Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 10/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778132 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAMAPTGAAHTT | |
| SCHEMBL504041 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAMAPTGAAHTT | |
| SCHEMBL10921898 | 0.83 | MAPT (0.50) | SMN1; SMN2LMNAMAPTGAAHTT | |
| SCHEMBL10921894 | 0.83 | MAPT (0.50) | SMN1; SMN2LMNAMAPTGAAHTT | |
| SCHEMBL482400 | 0.82 | LMNA (0.58) | SMN1; SMN2LMNAGAAHTTCYP1A2 | |
| SCHEMBL482402 | 0.82 | LMNA (0.58) | SMN1; SMN2LMNAGAAHTTCYP1A2 | |
| SCHEMBL5069532 | 0.81 | MAPT (0.49) | SMN1; SMN2LMNAMAPTGAAHTT | |
| SCHEMBL3605170 | 0.80 | MAPT (0.47) | SMN1; SMN2LMNAMAPTGAAHTT | |
| SCHEMBL13503036 | 0.80 | MAPT (0.47) | SMN1; SMN2LMNAMAPTGAAHTT | |
| SCHEMBL7536577 | 0.79 | LMNA (0.62) | SMN1; SMN2LMNAMAPTGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2818170-B1 | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | AMGEN INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-10053452-B2 | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof | AMGEN INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | AMGEN INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | AMGEN INC. | 2016-10-20 | — | — | US | disclosed |
| EP-3077392-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1 -PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF | Amgen Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160213669-A1 | USE OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-07-28 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015084649-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1 -PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF | AMGEN INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015084649-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1 -PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF | AMGEN INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1751136-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7151096-B2 | Cyclic compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-12-19 | — | — | US | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20040235841-A1 | Cyclic compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2004-11-25 | — | — | US | disclosed |
| WO-2004078682-A2 | CYCLIC COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | SMN1; SMN2 3987/4885LMNA 637/4885MAPT 1958/4885 |
| US-20160213669-A1 | USE OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF CANCER | HDAC4, HDAC9, HDAC5 | SMN1; SMN2 3612/4885LMNA 2181/4885MAPT 1123/4885 |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | BCL9, NPM1, MLLT3 | SMN1; SMN2 1415/4885LMNA 1963/4885MAPT 316/4885 |
| US-10053452-B2 | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof | BCL9, NPM1, MLLT3 | SMN1; SMN2 1415/4885LMNA 1963/4885MAPT 316/4885 |
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | SMN1; SMN2 3934/4885LMNA 3974/4885MAPT 1999/4885 |
| US-20040235841-A1 | Cyclic compounds and compositions as protein kinase inhibitors | CDK2, CDK5, CDK1 | SMN1; SMN2 2169/4885LMNA 1142/4885MAPT 1064/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | SMN1; SMN2 3923/4885LMNA 620/4885MAPT 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.